Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA)
-
Upload
metapresents -
Category
Health & Medicine
-
view
1.649 -
download
1
description
Transcript of Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA)
Andrew Chetley
Communication Director
MeTA Secretariat
Medicines Transparency Alliance: helping markets work for the poor
MeTA 10/04/23 1
10/04/23MeTA 2
MeTA numbers
26 key supporters (governments and organisations) 10 broad principles 7 pilot countries 3 essential stakeholder sectors 2 major commitments 4 areas of information disclosure 1 goal: improve access to essential medicines for
the 2 billion people who currently lack access
10/04/23MeTA 3
26 supporters of the objective of increased equitable access to medicines
Association of the British Pharmaceutical Industry
AstraZeneca Co-operative Investments Ecumenical Pharmaceutical Network F&C Investments GlaxoSmithKline Government of Peru Government of the Hashemite Kingdom of
Jordan Government of the Kyrgyz Republic
Government of the Republic of Ghana The Government of the Republic of the
Philippines Government of the Republic of Uganda Government of the United Kingdom Government of the Republic of Zambia
Health Action International Global Indian Pharmaceutical Association Institute for Democracy in South Africa International Federation of Pharmaceutical
Manufacturers and Associations International Pharmaceutical Federation Merck Novartis Partnership for Supply Chain Management SustainAbility Transparency International World Bank World Health Organization
…and growing daily …
10/04/23MeTA 4
10 Principles
1. Good health is crucial to human dignity and to social and economic development.2. Efforts to improve health depend on effective health systems 3. Inefficient procurement, distribution, and supply of medicines, weak regulation and
poor supply chain management, and lack of information can result in unaffordable/unavailable medicines.
4. Urgent action is required to address these challenges.5. Public understanding could inform public debate, enhance public policy and drive
improvements6. High standards of transparency can build trust and accountability .7. A multi-stakeholder approach can build understanding on how to develop greater
transparency and accountability. 8. Action to increase transparency and accountability should do no harm, support
national development and harmonisation plans, respect the rule of law and be guided by concerns for social justice,
9. We recognise the need to pilot and evaluate these actions.10. Our ultimate objective is to increase equitable access to medicines.
10/04/23MeTA 5
7 Pilot Countries
… pioneers, leaders, champions – innovators!… and an International Advisory Group
3 key stakeholder sectors
Public: (ministries – not only Health; health service managers and facilities; regulatory agencies; health and welfare insurance schemes)
Private: (manufacturers; wholesalers; distributors; retailers; private practitioners and services; private health insurance; investors)
Civil society: (communities, patients, consumers, transparency and rights groups, media, faith-based organisations)
2 major commitments
Progressive disclosure of data in four areas Development of an effective multi-stakeholder forum
– ‘All too often, government planners, business executives, and non-profit organisations have operated at cross-purposes and failed to coordinate their efforts in ways that would achieve shared goals.’ (Gupta, R. 2007. Health International, McKinsey & Co.)
… transparency and (mutual) accountability
4 disclosure areas; 4 contextual areas
Quality Availability Price Promotion
Supply chain operations Medicine affordability Equitable access Rational use
One goal
Increased access to essential medicines by poor people by:– shifting some decision making power– Increasing competitive pressure on suppliers– Improving the effectiveness of the supply chain– promoting better governance– ensuring more appropriate resource allocation– encouraging innovative and responsible business practices– Increasing the voice of patients and consumers
And improving people’s health!
10/04/23MeTA 10
Complexity: of the medicines supply system
Contra-ceptives and
RHequipment
STIDrugs
EssentialDrugs
Vaccinesand
Vitamin ATB/Leprosy
BloodSafety
Reagents(inc. HIV
tests)
DFID
KfW
UNICEF
JICA
GOK, WB/IDA
Source offunds for
commodities
CommodityType
(colour coded) MOHEquip-ment
Point of firstwarehousing KEMSA Central Warehouse
KEMSARegionalDepots
Organizationresponsible
for delivery todistrict levels
KEMSA and KEMSA Regional Depots (essential drugs, malaria drugs,
consumable supplies)
ProcurementAgent/Body
CrownAgents
Governmentof Kenya
GOK
GTZ(procurement
implementationunit)
JSI/DELIVER/KEMSA LogisticsManagement Unit (contraceptives,
condoms, STI kits, HIV test kits, TBdrugs, RH equipment etc)
EU
KfW
UNICEF
KEPI ColdStore
KEPI(vaccines
andvitamin A)
Malaria
USAID
USAID
UNFPA
EUROPA
Condomsfor STI/
HIV/AIDSprevention
CIDA
UNFPA
USGov
CDC
NPHLS store
MEDS(to Mission
facilities)
PrivateDrug
Source
GDF
Government
NGO/Private
Bilateral Donor
Multilateral Donor
World Bank Loan
Organization Key
JapanesePrivate
Company
WHO
GAVI
SIDA
NLTP(TB/
Leprosydrugs
Commodity Logistics System in Kenya (as of July 2006) Constructed and produced by Steve Kinzett, JSI/Kenya - please communicateany inaccuracies to [email protected] or telephone 2727210
Anti-RetroVirals
(ARVs)
Labor-atorysupp-lies
GlobalFund forAIDS, TB
and Malaria
PSCMC(CrownAgents,GTZ, JSI
and KEMSA)
BTC
MEDS
DANIDA
Mainly District level staff: DPHO, DPHN, DTLP, DASCO, DPHO, etc or staff from the Health Centres,Dispensaries come up and collect from the District level
MEDS
Provincial andDistrictHospital
LaboratoryStaff
Organizationresponsible fordelivery to sub-district levels
KNCV
MSF
MSF
JSI/DELIVER
KEMSA
JSI
WHO
Source: SSDS Inc for the World Bank
innovation
new and different voices
equity
dynamic dialogues
transformation
different perspectives
problem solving
mutual accountability
changing business practice
social justice
new partnerships
transparency
Complexity: of change
•18 months planning and consensus building •7 countries commit politically•Growing list of international stakeholders who support the concept•International Secretariat in place•International Advisory Group underway•International launch – “2nd phase of the peaceful revolution in international public health” now underway!
Achievements so far
MeTA 10/04/23 12
Peru: health insurance company brings down the price of medicines by 30% - who benefits?
Uganda: 50% of medicines for the public sector are found in the private sector – who pays twice?
Jordan: high prices include a government tax – united voices for change
Philippines: 2000 separate procurement approaches – how to avoid conflict of interest?
Four stories of change
MeTA 10/04/23 13
•How do we engage with new stakeholders (at every level) to increase support for the concept?•How do we work with the diversity at national level, yet still have meaningful sharing of lessons internationally?•How do we work towards multiple bottom lines: everyone wins (everyone prepared to give something away)?•What does success look like? (How will we know it has worked?)
Challenges we face
MeTA 10/04/23 14
10/04/23MeTA 15
More information
Contact the MeTA Secretariat– International Secretariat, [email protected]– Andrew Chetley, [email protected]
– www.MedicinesTransparency.org– and have your say: join in to MeTA-Dialogue – an
interactive discussion group at:
www.dgroups.org/groups/MeTADialogue/index.cfm